fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models
Open Access
- 23 June 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (9), 1984-1990
- https://doi.org/10.1093/jac/dkq226
Abstract
To elucidate the pharmacokinetic/pharmacodynamic (PK/PD) index that predicts colistin efficacy against Acinetobacter baumannii in neutropenic murine thigh and lung infection models, and to determine the extent of the emergence of resistance in vivo to colistin. PK/PD of colistin was studied in thigh and lung infection models against A. baumannii ATCC 19606 and two multidrug-resistant clinical isolates (two of the three strains were colistin heteroresistant). Dose fractionation studies were conducted over a daily dose range of 1–160 mg/kg colistin sulphate. Bacterial burden in tissues was measured at 24 h. Non-linear least squares regression analyses were employed to determine the PK/PD index (fAUC/MIC, fCmax/MIC or fT>MIC) best correlating with the efficacy of colistin in each model. Real-time population analysis profiles were conducted for tissue samples to monitor the emergence of resistance. The fAUC/MIC was the PK/PD index that correlated best with efficacy in both thigh (R2 = 0.90) and lung (R2 = 0.80) infection models. The fAUC/MIC targets required to achieve stasis and 1 log kill against the three strains were 1.89–7.41 and 6.98–13.6 in the thigh infection model, respectively, while the corresponding values were 1.57–6.52 and 8.18–42.1 in the lung infection model. Amplification of colistin-resistant subpopulations was revealed for all strains in both models after 24 h colistin treatment. This study indicates the importance of achieving adequate time-averaged exposure to colistin and defined target fAUC/MIC values for various magnitudes of kill. Amplification of resistant subpopulations indicates the importance of investigating rational combinations with colistin. The results will facilitate efforts to optimize colistin use in humans.This publication has 22 references indexed in Scilit:
- Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection ModelsAntimicrobial Agents and Chemotherapy, 2010
- Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2006
- Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous HemodiafiltrationAntimicrobial Agents and Chemotherapy, 2005
- Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonateJournal of Antimicrobial Chemotherapy, 2004
- Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosisJournal of Antimicrobial Chemotherapy, 2003
- Stability of Colistin and Colistin Methanesulfonate in Aqueous Media and Plasma as Determined by High-Performance Liquid ChromatographyAntimicrobial Agents and Chemotherapy, 2003
- The Pharmacokinetics of Colistin in Patients with Cystic FibrosisThe Journal of Clinical Pharmacology, 2001
- Changes in the Serum Protein Binding of Vancomycin in Patients with Methicillin-Resistant Staphylococcus aureus InfectionTherapeutic Drug Monitoring, 1995
- Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection.Heart, 1982